Citius Oncology (CTOR)
Market Price (7/17/2026): $0.689 | Market Cap: $68.9 MilSector: Health Care | Industry: Pharmaceuticals
Citius Oncology (CTOR)
Market Price (7/17/2026): $0.689Market Cap: $68.9 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -45% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -129%, 3Y Excs Rtn is -163% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.39 | Penny stockMkt Price is 0.7 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -44 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -776% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 212% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -297%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -386% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -67% Key risksCTOR key risks include [1] its overwhelming dependence on the commercial success of a single product, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -45% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -129%, 3Y Excs Rtn is -163% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.39 |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -44 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -776% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 212% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -297%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -386% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -67% |
| Key risksCTOR key risks include [1] its overwhelming dependence on the commercial success of a single product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/15/2026
Citius Oncology (CTOR) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Continued strong commercial progress for LYMPHIR in the U.S.
Citius Oncology reported significant advancements in the commercialization of its lead product, LYMPHIR. Early metrics shared on March 31, 2026, highlighted sequential order growth, with 83% of target accounts either having LYMPHIR on formulary or actively reviewing it. Furthermore, the company achieved near 100% commercial payer coverage, with no reported reimbursement denials. The fiscal Q2 2026 (which ended March 31, 2026) results, reported on May 15, 2026, further confirmed LYMPHIR generated $1.7 million in net revenue for the quarter and $5.6 million for the first half of fiscal 2026, maintaining approximately 80% gross margins, signaling successful initial market penetration and adoption.
2. Expansion of LYMPHIR into international markets.
On April 29, 2026, Citius Oncology announced its first international shipment of LYMPHIR to Europe through a regional distribution partner. This strategic move facilitated patient access outside the United States by making LYMPHIR available via Named Patient Programs in specific European countries under local regulations, marking a key step in broadening the drug's market reach.
Show more
Citius Oncology (CTOR) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Continued strong commercial progress for LYMPHIR in the U.S.
Citius Oncology reported significant advancements in the commercialization of its lead product, LYMPHIR. Early metrics shared on March 31, 2026, highlighted sequential order growth, with 83% of target accounts either having LYMPHIR on formulary or actively reviewing it. Furthermore, the company achieved near 100% commercial payer coverage, with no reported reimbursement denials. The fiscal Q2 2026 (which ended March 31, 2026) results, reported on May 15, 2026, further confirmed LYMPHIR generated $1.7 million in net revenue for the quarter and $5.6 million for the first half of fiscal 2026, maintaining approximately 80% gross margins, signaling successful initial market penetration and adoption.
2. Expansion of LYMPHIR into international markets.
On April 29, 2026, Citius Oncology announced its first international shipment of LYMPHIR to Europe through a regional distribution partner. This strategic move facilitated patient access outside the United States by making LYMPHIR available via Named Patient Programs in specific European countries under local regulations, marking a key step in broadening the drug's market reach.
Show more
Updated on 7/15/2026
Citius Oncology (CTOR) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Continued strong commercial progress for LYMPHIR in the U.S.
Citius Oncology reported significant advancements in the commercialization of its lead product, LYMPHIR. Early metrics shared on March 31, 2026, highlighted sequential order growth, with 83% of target accounts either having LYMPHIR on formulary or actively reviewing it. Furthermore, the company achieved near 100% commercial payer coverage, with no reported reimbursement denials. The fiscal Q2 2026 (which ended March 31, 2026) results, reported on May 15, 2026, further confirmed LYMPHIR generated $1.7 million in net revenue for the quarter and $5.6 million for the first half of fiscal 2026, maintaining approximately 80% gross margins, signaling successful initial market penetration and adoption.
2. Expansion of LYMPHIR into international markets.
On April 29, 2026, Citius Oncology announced its first international shipment of LYMPHIR to Europe through a regional distribution partner. This strategic move facilitated patient access outside the United States by making LYMPHIR available via Named Patient Programs in specific European countries under local regulations, marking a key step in broadening the drug's market reach.
3. Successful capital raise bolstering liquidity and future operations.
In early May 2026, subsequent to fiscal Q2 2026, Citius Oncology secured substantial financing of up to $36.5 million. This capital infusion included a senior secured credit facility of up to $25 million (with an initial $10 million funded) and approximately $11.5 million from the immediate exercise of outstanding warrants. This financing is projected to support the continued commercialization of LYMPHIR and general operations through November 2026, addressing near-term funding requirements.
4. Positive clinical trial data for LYMPHIR combination studies.
Citius Oncology presented encouraging Phase 1 data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the ASCO 2026 Annual Meeting in May and June 2026. This investigator-initiated trial demonstrated an objective response rate of 24% and a favorable safety profile, indicating LYMPHIR's potential to enhance the efficacy of immune checkpoint inhibitors and expand its therapeutic applications beyond its initial indication. Positive topline safety and efficacy results were also noted for an investigator-initiated Phase 1 trial evaluating LYMPHIR prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma.
Show less
Citius Oncology (CTOR) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Continued strong commercial progress for LYMPHIR in the U.S.
Citius Oncology reported significant advancements in the commercialization of its lead product, LYMPHIR. Early metrics shared on March 31, 2026, highlighted sequential order growth, with 83% of target accounts either having LYMPHIR on formulary or actively reviewing it. Furthermore, the company achieved near 100% commercial payer coverage, with no reported reimbursement denials. The fiscal Q2 2026 (which ended March 31, 2026) results, reported on May 15, 2026, further confirmed LYMPHIR generated $1.7 million in net revenue for the quarter and $5.6 million for the first half of fiscal 2026, maintaining approximately 80% gross margins, signaling successful initial market penetration and adoption.
2. Expansion of LYMPHIR into international markets.
On April 29, 2026, Citius Oncology announced its first international shipment of LYMPHIR to Europe through a regional distribution partner. This strategic move facilitated patient access outside the United States by making LYMPHIR available via Named Patient Programs in specific European countries under local regulations, marking a key step in broadening the drug's market reach.
3. Successful capital raise bolstering liquidity and future operations.
In early May 2026, subsequent to fiscal Q2 2026, Citius Oncology secured substantial financing of up to $36.5 million. This capital infusion included a senior secured credit facility of up to $25 million (with an initial $10 million funded) and approximately $11.5 million from the immediate exercise of outstanding warrants. This financing is projected to support the continued commercialization of LYMPHIR and general operations through November 2026, addressing near-term funding requirements.
4. Positive clinical trial data for LYMPHIR combination studies.
Citius Oncology presented encouraging Phase 1 data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the ASCO 2026 Annual Meeting in May and June 2026. This investigator-initiated trial demonstrated an objective response rate of 24% and a favorable safety profile, indicating LYMPHIR's potential to enhance the efficacy of immune checkpoint inhibitors and expand its therapeutic applications beyond its initial indication. Positive topline safety and efficacy results were also noted for an investigator-initiated Phase 1 trial evaluating LYMPHIR prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 10.0% change in CTOR stock from 3/31/2026 to 7/16/2026 was primarily driven by a 42.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.62 | 0.68 | 10.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 6 | 42.3% |
| P/S Multiple | 13.7 | 12.2 | -11.6% |
| Shares Outstanding (Mil) | 87 | 100 | -12.6% |
| Cumulative Contribution | 10.0% |
Market Drivers
3/31/2026 to 7/16/2026| Return | Correlation | |
|---|---|---|
| CTOR | 10.0% | |
| Market (SPY) | 15.4% | 23.9% |
| Sector (XLV) | 10.4% | -0.3% |
Fundamental Drivers
The -31.8% change in CTOR stock from 12/31/2025 to 7/16/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.00 | 0.68 | -31.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 6 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 12.2 | |
| Shares Outstanding (Mil) | 78 | 100 | -21.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/16/2026| Return | Correlation | |
|---|---|---|
| CTOR | -31.8% | |
| Market (SPY) | 10.4% | 37.7% |
| Sector (XLV) | 5.0% | 21.7% |
Fundamental Drivers
The -84.3% change in CTOR stock from 6/30/2025 to 7/16/2026 was primarily driven by a -28.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.35 | 0.68 | -84.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 6 | 0.0% |
| P/S Multiple | � | 12.2 | 0.0% |
| Shares Outstanding (Mil) | 71 | 100 | -28.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/16/2026| Return | Correlation | |
|---|---|---|
| CTOR | -84.3% | |
| Market (SPY) | 22.5% | 26.7% |
| Sector (XLV) | 21.6% | 15.5% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/16/2026| Return | Correlation | |
|---|---|---|
| CTOR | -93.5% | |
| Market (SPY) | 75.3% | -0.9% |
| Sector (XLV) | 27.6% | -4.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CTOR Return | - | 1% | 8% | -89% | -13% | -31% | -93% |
| Peers Return | -39% | -50% | 8% | -13% | -1% | -3% | -72% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| CTOR Win Rate | - | 100% | 100% | 50% | 25% | 57% | |
| Peers Win Rate | 44% | 39% | 36% | 42% | 47% | 43% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| CTOR Max Drawdown | - | - | -2% | -98% | -81% | -60% | |
| Peers Max Drawdown | -67% | -75% | -76% | -70% | -57% | -51% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TGTX, VSTM, SNGX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/16/2026 (YTD)
How Low Can It Go
| Event | CTOR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -52.4% | -18.8% |
| % Gain to Breakeven | 110.1% | 23.1% |
| Time to Breakeven | 83 days | 79 days |
In The Past
Citius Oncology's stock fell -52.4% during the 2025 US Tariff Shock. Such a loss loss requires a 110.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CTOR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -52.4% | -18.8% |
| % Gain to Breakeven | 110.1% | 23.1% |
| Time to Breakeven | 83 days | 79 days |
In The Past
Citius Oncology's stock fell -52.4% during the 2025 US Tariff Shock. Such a loss loss requires a 110.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Citius Oncology (CTOR)
```html
Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on the development and commercialization of innovative targeted therapies for cancer. The company aims to bring advanced treatments to market, addressing specific oncology indications.
Its primary product is LYMPHIR™ (denileukin diftitox-cxdl), a targeted immune therapy that received U.S. FDA approval in August 2024. LYMPHIR™ is specifically indicated for patients diagnosed with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and chronic type of non-Hodgkin lymphoma. This makes the company's main customers patients suffering from this particular form of skin lymphoma.
Citius Oncology, Inc. is also structured as a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Citius Oncology (CTOR):
- Like a startup Genentech (pre-Roche) focused on targeted cancer therapies, with a newly FDA-approved drug.
- An emerging Bristol Myers Squibb (BMS is an oncology leader) that just launched its first targeted cancer therapy.
- Similar to Vertex Pharmaceuticals (known for successful targeted therapies) but focused on launching a niche oncology drug.
AI Analysis | Feedback
- LYMPHIR™ (denileukin diftitox-cxdl): A targeted immune therapy approved for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
AI Analysis | Feedback
Citius Oncology (CTOR), as a biopharmaceutical company, sells its approved therapy, LYMPHIR™, through established pharmaceutical distribution channels. The company's primary customers are major pharmaceutical wholesale distributors, who then supply hospitals, specialty pharmacies, and other healthcare providers.
The major customer companies for Citius Oncology would typically include:
- McKesson Corporation (NYSE: MCK)
- Cardinal Health, Inc. (NYSE: CAH)
- AmerisourceBergen Corporation (NYSE: ABC)
AI Analysis | Feedback
Citius Oncology (CTOR) identifies Wacker Biotech GmbH as a major supplier for the active pharmaceutical ingredient (API) for LYMPHIR. Wacker Biotech GmbH is a subsidiary of Wacker Chemie AG, a public company.
- Wacker Chemie AG (XTRA: WCH)
AI Analysis | Feedback
Leonard Mazur, Chief Executive Officer and Executive Chairman of the Board
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with over five decades of experience in founding and building healthcare companies. He is the co-founder and Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He previously co-founded Akrimax Pharmaceuticals, LLC, and from 2005 to 2012, co-founded and served as Chief Operating Officer of Triax Pharmaceuticals LLC. As the founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., he successfully negotiated its sale to Pierre Fabre, a leading global pharmaceutical company, in 2003.
Jaime Bartushak, Chief Financial Officer and Treasurer
Mr. Bartushak is an experienced finance and operations professional for early-stage pharmaceutical companies, with over 20 years of expertise in corporate finance, business development, M&A, restructuring, capital formation, and strategic planning. He was a founder of Leonard-Meron Biosciences and, as CFO, was instrumental in obtaining initial investment capital for its start-up in 2014. Earlier in his career, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc., and prior to that, he led the financial efforts for the successful sale of Triax Pharmaceuticals to PreCision Dermatology.
Dr. Myron S. Czuczman, Chief Medical Officer and Executive Vice President
Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharma executive with decades of experience in the strategic design, implementation, and oversight of global development for novel therapeutics for hematologic malignancies. He joined Citius from Celgene, where he served as Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL, managing a global team responsible for compound development from proof-of-principle to worldwide registration. Before his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center, where he was chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory.
Myron Holubiak, Executive Vice Chairman of the Board, Secretary, and Director
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. He was the co-founder, director, and CEO of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. From 1998 to 2001, Mr. Holubiak served as President of Roche Laboratories, Inc., where he helped transform Roche Labs into a leading antibiotic and biotechnology company. During his 19-year tenure at Roche Labs, he held multiple sales and marketing roles.
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with over five decades of experience in founding and building healthcare companies. He is the co-founder and Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He previously co-founded Akrimax Pharmaceuticals, LLC, and from 2005 to 2012, co-founded and served as Chief Operating Officer of Triax Pharmaceuticals LLC. As the founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., he successfully negotiated its sale to Pierre Fabre, a leading global pharmaceutical company, in 2003.
Jaime Bartushak, Chief Financial Officer and Treasurer
Mr. Bartushak is an experienced finance and operations professional for early-stage pharmaceutical companies, with over 20 years of expertise in corporate finance, business development, M&A, restructuring, capital formation, and strategic planning. He was a founder of Leonard-Meron Biosciences and, as CFO, was instrumental in obtaining initial investment capital for its start-up in 2014. Earlier in his career, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc., and prior to that, he led the financial efforts for the successful sale of Triax Pharmaceuticals to PreCision Dermatology.
Dr. Myron S. Czuczman, Chief Medical Officer and Executive Vice President
Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharma executive with decades of experience in the strategic design, implementation, and oversight of global development for novel therapeutics for hematologic malignancies. He joined Citius from Celgene, where he served as Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL, managing a global team responsible for compound development from proof-of-principle to worldwide registration. Before his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center, where he was chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory.
Myron Holubiak, Executive Vice Chairman of the Board, Secretary, and Director
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. He was the co-founder, director, and CEO of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. From 1998 to 2001, Mr. Holubiak served as President of Roche Laboratories, Inc., where he helped transform Roche Labs into a leading antibiotic and biotechnology company. During his 19-year tenure at Roche Labs, he held multiple sales and marketing roles.
AI Analysis | Feedback
Citius Oncology (NASDAQ: CTOR), a biopharmaceutical company focused on targeted oncology therapies with its FDA-approved drug LYMPHIR™ (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma (CTCL), faces several key risks to its business operations and future prospects.
- Significant Financial Strain and Going Concern Risk
Citius Oncology is experiencing substantial financial challenges, characterized by a negative operating margin of -552.92% and a net margin of -599.32%. The company's current ratio of 0.83 indicates potential liquidity issues, and an Altman Z-Score of -0.56 places it in the "distress zone," suggesting a possibility of bankruptcy within the next two years. The commercialization of LYMPHIR™ has faced repeated delays and requires considerable upfront capital investment. The company has relied on warrant-based financing and requires substantial additional funds to sustain its operations. Even its parent company, Citius Pharmaceuticals, is reportedly experiencing negative cash flow and limited cash reserves. - Uncertainty in Commercialization and Market Adoption of LYMPHIR™
Despite the U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ in August 2024 and its subsequent launch in December 2025, there is significant uncertainty regarding its ability to achieve sustainable commercial success. Citius Oncology must commit substantial capital before seeing tangible revenue, and the market adoption and return on investment for LYMPHIR™ are projected to be gradual and unpredictable. The company faces potential hurdles related to efficacy, safety, manufacturing, labeling, and market acceptance, which could limit approvals, restrict indications, or prevent commercialization entirely. Competition within the estimated $400-500 million CTCL market, along with delays in the drug's launch and a lack of clear commercial partnerships, further amplify this risk. - Single Product Reliance and Pipeline Development Risks
Citius Oncology's business is heavily reliant on the success of LYMPHIR™, which currently appears to be its primary, and potentially sole, FDA-approved commercial product. While the company aims to develop and commercialize other innovative targeted oncology therapies and is conducting investigator-initiated studies for LYMPHIR™ in combination with other drugs for different cancers (e.g., Phase 1 for gynecologic cancers), these are in early stages. Therefore, any challenges affecting LYMPHIR™'s market acceptance, reimbursement, or unforeseen post-marketing issues would significantly impact the company's financial performance and overall viability due to this concentrated product portfolio.
AI Analysis | Feedback
null
AI Analysis | Feedback
Citius Oncology's main product, LYMPHIR™ (denileukin diftitox-cxdl), targets patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company estimates that LYMPHIR is entering a U.S. market valued at over $400 million. This estimate also suggests further growth opportunities through international expansion and potential label extensions.
For broader context, the overall Cutaneous T-Cell Lymphoma market size in the 7MM (United States, EU4, UK, and Japan) was valued at approximately USD 1,042 million in 2025 and is projected to reach USD 1,622 million by 2034. Within the 7MM, the United States accounted for the largest share of the CTCL market, approximately 70% in 2024, generating an estimated revenue of USD 700 million in 2024.
AI Analysis | Feedback
Citius Oncology (NASDAQ: CTOR) is anticipated to drive future revenue growth over the next two to three years through several key strategies, primarily centered around its recently launched targeted immune therapy, LYMPHIR™ (denileukin diftitox-cxdl).
Here are the expected drivers of future revenue growth:
- Commercialization and Market Penetration of LYMPHIR™ in Cutaneous T-Cell Lymphoma (CTCL): LYMPHIR™ was commercially launched in the U.S. in December 2025 for adults with relapsed or refractory Stage I–III CTCL. Management projects the initial market for LYMPHIR™ to exceed $400 million, noting it is growing and currently underserved by existing therapies. Citius Oncology is focused on accelerating physician adoption, expanding patient access, and utilizing an advanced AI-enabled commercial platform to drive efficient market penetration.
- Expansion of LYMPHIR™ into New Indications: Citius Oncology plans to explore the potential of LYMPHIR™ to treat larger patient populations by expanding its indications. The drug is already approved in Japan for both CTCL and Peripheral T-Cell Lymphoma (PTCL), suggesting a potential U.S. label expansion into PTCL. Furthermore, positive topline results from an investigator-initiated Phase 1 study evaluating LYMPHIR™ in combination with pembrolizumab in relapsed or refractory gynecologic cancers indicate potential for use in solid tumors. Additionally, a Phase 1 trial showed an 86% objective response rate when LYMPHIR™ was administered prior to CAR-T therapy in high-risk relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients, pointing to another promising area for expansion.
- International Market Expansion for LYMPHIR™: Citius Oncology has initiated efforts to broaden access to LYMPHIR™ beyond the U.S. by establishing distribution partnerships for Named Patient Programs across 19 markets in Southern Europe and the Middle East. This strategic move aims to scale the therapy globally and contribute to future revenue.
- Strong Intellectual Property and Orphan Drug Exclusivity: LYMPHIR™ benefits from robust intellectual property protections, including orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology applications, particularly as a combination therapy. As a new biologic approved by the FDA, LYMPHIR™ is also potentially eligible for 12 years of market exclusivity, providing a strong competitive advantage and a sustained revenue stream.
AI Analysis | Feedback
```html
```
Capital Allocation Decisions for Citius Oncology (CTOR) over the Last 3-5 Years
Share Issuance
- Citius Oncology became a publicly traded company on August 13, 2024, following a merger that resulted in its listing on the Nasdaq stock exchange under the symbol CTOR.
- In July 2025, Citius Oncology completed a public offering of common stock and warrants, generating approximately $9.0 million in gross proceeds.
- The company conducted additional financing activities in fiscal year 2025, including a $9 million concurrent registered direct offering and private placement in September 2025 and an $18 million concurrent registered direct offering and private placement in December 2025.
Inbound Investments
- Citius Pharmaceuticals, Inc. (CTXR) maintains a majority ownership, holding approximately 90% of Citius Oncology following the latter's public listing.
Capital Expenditures
- Citius Oncology has reported "N/A" for Capital Expenditures in its recent financial statements, suggesting a lack of significant traditional capital expenditures.
- The company's operating expenses, including research and development, have increased, reflecting its focus on advancing oncology therapies rather than significant physical asset acquisition.
- Research and Development expenses amounted to approximately $6.75 million over the last twelve months, indicating investment in drug development.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.23 |
| Mkt Cap | 0.3 |
| Rev LTM | 28 |
| Op Inc LTM | -28 |
| FCF LTM | -18 |
| FCF 3Y Avg | -18 |
| CFO LTM | -15 |
| CFO 3Y Avg | -18 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 238.6% |
| Rev Chg 3Y Avg | 1,130.2% |
| Rev Chg Q | 69.6% |
| QoQ Delta Rev Chg LTM | 42.3% |
| Op Inc Chg LTM | -21.5% |
| Op Inc Chg 3Y Avg | -4.5% |
| Op Mgn LTM | -344.6% |
| Op Mgn 3Y Avg | 17.8% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | -297.2% |
| CFO/Rev 3Y Avg | -3.6% |
| FCF/Rev LTM | -307.1% |
| FCF/Rev 3Y Avg | -3.6% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Developing and commercializing innovative targeted oncology therapies | 0 | |||
| Single segment | 0 | 0 | 0 | |
| Total | 0 | 0 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Developing and commercializing innovative targeted oncology therapies | 101 | |||
| Single segment | 84 | 48 | 43 | |
| Total | 101 | 84 | 48 | 43 |
Price Behavior
Price Behavior
| Market Price | $0.68 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/08/2022 | |
| Distance from 52W High | -69.1% | |
| 50 Days | 200 Days | |
| DMA Price | $0.79 | $1.07 |
| DMA Trend | down | down |
| Distance from DMA | -13.9% | -36.5% |
| 3M | 1YR | |
| Volatility | 76.5% | 85.9% |
| Downside Capture | 174.32 | 222.06 |
| Upside Capture | 52.52 | 74.15 |
| Correlation (SPY) | 23.2% | 29.8% |
CTOR Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.73 | 1.56 | 2.68 | 2.33 | 2.17 | -0.09 |
| Up Beta | 3.72 | 1.71 | 4.26 | 3.85 | 4.44 | 0.06 |
| Down Beta | 0.44 | 0.08 | 1.02 | 1.46 | 1.74 | -1.00 |
| Up Capture | 48% | 72% | 241% | 142% | 1% | -5% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 8 | 16 | 29 | 49 | 105 | 276 |
| Down Capture | 238% | 295% | 223% | 208% | 179% | 92% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 13 | 25 | 34 | 72 | 134 | 282 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTOR | |
|---|---|---|---|---|
| CTOR | -55.9% | 85.7% | -0.58 | - |
| Sector ETF (XLV) | 23.7% | 15.9% | 1.15 | 12.9% |
| Equity (SPY) | 21.8% | 12.6% | 1.29 | 30.0% |
| Gold (GLD) | 19.1% | 28.0% | 0.61 | 16.3% |
| Commodities (DBC) | 27.9% | 18.9% | 1.16 | 3.2% |
| Real Estate (VNQ) | 16.9% | 14.0% | 0.88 | 12.7% |
| Bitcoin (BTCUSD) | -45.3% | 42.8% | -1.29 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTOR | |
|---|---|---|---|---|
| CTOR | -2.9% | 167.7% | 0.50 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.24 | -2.7% |
| Equity (SPY) | 13.2% | 17.1% | 0.60 | 1.0% |
| Gold (GLD) | 16.7% | 18.4% | 0.73 | -0.5% |
| Commodities (DBC) | 8.5% | 19.5% | 0.33 | 3.7% |
| Real Estate (VNQ) | 3.2% | 18.9% | 0.07 | -3.7% |
| Bitcoin (BTCUSD) | 14.5% | 53.5% | 0.45 | -8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTOR | |
|---|---|---|---|---|
| CTOR | -1.5% | 167.7% | 0.50 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | -2.7% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 1.0% |
| Gold (GLD) | 10.9% | 16.1% | 0.55 | -0.5% |
| Commodities (DBC) | 6.5% | 18.0% | 0.28 | 3.7% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.22 | -3.7% |
| Bitcoin (BTCUSD) | 57.8% | 66.2% | 0.98 | -8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/18/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/15/2026 | -14.0% | -12.8% | -31.4% |
| 2/13/2026 | 3.4% | -1.7% | -31.7% |
| 12/23/2025 | -9.8% | -21.3% | -13.4% |
| 8/12/2025 | 5.9% | 0.6% | 11.8% |
| 5/14/2025 | -0.6% | -1.7% | 65.1% |
| 12/27/2024 | 7.7% | 48.1% | 21.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 3 | 4 | 3 |
| Median Positive | 5.9% | 24.3% | 21.2% |
| Median Negative | -9.8% | -7.3% | -31.4% |
| Max Positive | 7.7% | 48.1% | 65.1% |
| Max Negative | -14.0% | -21.3% | -31.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/15/2026 | -14.0% | -12.8% | -31.4% |
| 2/13/2026 | 3.4% | -1.7% | -31.7% |
| 12/23/2025 | -9.8% | -21.3% | -13.4% |
| 8/12/2025 | 5.9% | 0.6% | 11.8% |
| 5/14/2025 | -0.6% | -1.7% | 65.1% |
| 12/27/2024 | 7.7% | 48.1% | 21.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 3 | 4 | 3 |
| Median Positive | 5.9% | 24.3% | 21.2% |
| Median Negative | -9.8% | -7.3% | -31.4% |
| Max Positive | 7.7% | 48.1% | 65.1% |
| Max Negative | -14.0% | -21.3% | -31.7% |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/16/2026